SuZhou Bright Scistar Biotechnology

Suzhou Bright Scistar Biotechnology is a Chinese biotechnology company founded in 2013 that specializes in the research, development, and commercialization of antibodies and reagents targeting costimulatory molecules. Based in the Suzhou Med Park and closely affiliated with Soochow University through a joint laboratory, the company provides a wide range of research tools, including ELISA kits and validated monoclonal antibodies for immune checkpoint proteins like B7-H3, B7-H4, and VISTA. Beyond its reagent business, Bright Scistar is advancing a pipeline of therapeutic candidates, including humanized antibodies, antibody-drug conjugates (ADCs), and radionuclide drug conjugates (RDCs) for oncology indications such as glioblastoma. The company's R&D is led by Professor Zhang Xueguang, a prominent figure in clinical immunology, and focuses on translating academic research into clinical applications.